Drug Trial Radar · NCT01851330
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)
Last checked: Nov 19, 2026Latest source record: Nov 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
647
Actual
Start
May 2013
Primary completion
Dec 2013
Study completion Mar 2014
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- May 10, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV) administered for 8 or 12 weeks in treatment-naive participants with chronic genotype 1 HCV infection.
Conditions
- Chronic Hepatitis C Virus
Interventions
LDV/SOFDrug
LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
RBVDrug
Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)Time frame: Posttreatment Week 12
- Incidence of Adverse Events Leading to Permanent Discontinuation From Any Study DrugTime frame: Up to 12 weeks
Locations
52 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
La Jolla, California
Site not named
Los Angeles, California
Site not named
Palo Alto, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
Aurora, Colorado
Site not named
Englewood, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Gainesville, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Wellington, Florida
Site not named
Atlanta, Georgia
Site not named
Decatur, Georgia
Site not named
Marietta, Georgia
Site not named
Chicago, Illinois
Site not named
Indianapolis, Indiana
Site not named
Bowling Green, Kentucky
Site not named
Baton Rouge, Louisiana
Site not named
Baltimore, Maryland
Site not named
Lutherville, Maryland
Site not named
Boston, Massachusetts
Site not named
Novi, Michigan
Site not named
Kansas City, Missouri
Site not named
St Louis, Missouri
Site not named
Albuquerque, New Jersey
Site not named
Berlin, New Jersey
Site not named
Hillsborough, New Jersey
Site not named
Santa Fe, New Mexico
Site not named
Binghamton, New York
Site not named
Manhasset, New York
Site not named
New York, New York
Site not named
Chapel Hill, North Carolina
Site not named
Fayetteville, North Carolina
Site not named
Statesville, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Philadelphia, Pennsylvania
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.